At the 2025 ASCRS meeting, Dr. Sarkisian presented 3-year data on the iDose TR from the FDA clinical trial.
Steven R. Sarkisian Jr., MD, ABO
Advertisement
Articles by Steven R. Sarkisian Jr., MD, ABO
Advertisement
Latest Updated Articles
Nitric Oxide and Its Important Role in the Trabecular Meshwork of Glaucoma PatientsPublished: December 21st 2018 | Updated:
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Sight Sciences reports new data supporting long-term efficacy of OMNI Surgical System
2
When policy meets parenthood: Examining residency leave in ophthalmology
3
Post-hoc AREDS2 analysis highlights distinct mechanisms driving GA progression
4
AAO 2025: 12-month outcomes of travoprost intracameral implant (iDose TR) in conjunction with cataract surgery
5
.png "Optometry Times"){kind=logo}
